CDSCO Guidance on Good Clinical Practices: Overview

The Central Drugs Standard Control Organization (CDSCO), India’s apex regulatory authority for healthcare products, published draft GCP guidelines in September 2024 for a 30-day public consultation period. Those guidelines were drafted in alignment with the New Drugs and Clinical Trial (NDCT) Rules, 2019 and drew significantly on international frameworks including ICH E6(R3). The document provides an overview of the principles and approaches governing clinical trials involving healthcare products in India, with clarifications and recommendations for manufacturers, sponsors, and other parties responsible for ensuring compliance.

Introduction

The development of Good Clinical Practices (GCP) has its roots in the Hippocratic Oath, the fundamental ethical principle in medicine that urges practitioners to “do no harm”. While the oath was sufficient in ancient times, the complexities of modern biomedical research necessitate more detailed and specific guidelines.

GCP is a comprehensive set of standards that govern the design, conduct, analysis, and documentation of clinical trials involving human participants. These guidelines ensure that research conducted on human subjects is ethical and scientifically sound, protecting the rights, safety, and well-being of the participants while ensuring the authenticity of the data collected.

The key principle of GCP is that the interests of science and society should never overshadow the well-being of study participants. It also ensures that the clinical properties of drugs or treatments under investigation are thoroughly documented.

By following GCP, research organizations can produce reliable data while maintaining the highest ethical standards.

Scope and Flexibility

The guidelines published by the CDSCO are structured to accommodate a wide range of clinical research designs. They encourage careful planning and consideration of each study’s unique aspects, such as the nature of the investigational product, the medical condition being studied, the characteristics of the participants, and the type of data being collected.

This flexibility allows for the adaptation of the guidelines to suit different research methodologies while maintaining the quality and reliability of the research. The 2024 CDSCO draft guidelines gave specific attention to digital health technologies, wearables, and sensors as tools for data collection and broader participant inclusion. This focus reflects the broader direction of global GCP modernization. The ICH finalized its updated GCP guideline, E6(R3), in January 2025, a significant international development that India’s draft guidelines largely mirror in their approach to technology, decentralized trial methods, and risk-based quality management. The EMA adopted E6(R3) effective July 2025, the FDA finalized its E6(R3) guidance in September 2025, and the UK plans implementation in April 2026. India’s CDSCO is expected to align its final GCP guidelines with E6(R3) themes, making it important for sponsors conducting trials in India to also be aware of these international developments.

These technologies can help streamline data collection and improve the inclusiveness of clinical trials by allowing a broader range of participants to be involved. Importantly, these innovations should be tailored to the specific characteristics of the study participants and the research design.

Stakeholder Involvement

The design of a clinical study should not only be grounded in scientific principles but should also involve input from a wide array of stakeholders. These include patients, healthcare providers, regulators, and other relevant parties.

This collaborative regulation approach ensures that the research is more likely to yield meaningful outcomes that are relevant to both current study participants and future patients. Stakeholder input is also crucial for determining the feasibility of data collection and ensuring that participation in the research is not unduly burdensome for participants.

For instance, feedback from patients can provide valuable insights into the practical aspects of clinical trial participation, such as the frequency of visits, the types of data collected, and the overall convenience of the trial procedures.

National and International Alignment

These GCP guidelines have been developed in consideration of national and international standards. They align with the New Drugs and Clinical Trial (NDCT) Rules, 2019 and are in harmony with guidelines from the World Health Organization (WHO), the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), the United States Food and Drug Administration (USFDA), and the European Medicines Agency (EMA).

The international alignment referenced in this section has become more concrete since the guidelines were drafted. ICH E6(R3), the updated global GCP standard, was finalized in January 2025 and has since been adopted by the EMA (effective July 2025) and the FDA (September 2025). India’s CDSCO draft guidelines were developed to be broadly consistent with E6(R3)’s emphasis on risk-based approaches, decentralized trial designs, electronic consent, and quality by design. Sponsors operating in India should review their trial frameworks against both the CDSCO draft and ICH E6(R3) to ensure alignment as both frameworks converge.

Additionally, India’s Digital Personal Data Protection Rules, published in November 2025, introduce an 18-month phased compliance timeline for data protection obligations. Clinical trial sponsors collecting digital personal data in India should assess their data management practices against these new rules, which interact directly with GCP data governance requirements.

The guidelines introduce and define several critical terms used in clinical research, which are vital for understanding the scope and application of GCP.

The terms described in the guidelines include inter alia, the following ones:

• Academic Clinical Study: Research initiated by academic or research institutions on drugs already approved for a specific claim, focusing on new indications or dosages for academic purposes rather than regulatory approval.
• Adaptive Clinical Study: A design that allows for real-time modifications based on data generated during the study.
• Adverse Event (AE): Any untoward medical occurrence in a patient or participant receiving a treatment, whether or not it is related to the treatment.
• Adverse Drug Reaction (ADR): A harmful and unintended response to a drug that appears to be related to the treatment being administered.
• Audit: A systematic review of study-related activities and records to ensure compliance with the protocol and regulatory requirements.

The 2024 draft guidelines also introduce new definitions not present in earlier Indian GCP frameworks, including Electronic Informed Consent (e-Consent) and Decentralized Clinical Trials — reflecting the growing role of remote and technology-enabled trial methods. Sponsors designing trials with these elements should review the specific definitions in the CDSCO draft carefully, as India’s interpretation may differ in detail from other jurisdictions.

Phases of Clinical Trials

The guidelines classify clinical trials into several phases, each with distinct objectives:

• Phase I: Focuses on the safety and tolerability of a drug. This phase typically involves a small group of healthy volunteers or patients.
• Phase II: Evaluates the effectiveness of the drug for a specific condition, involving a larger group of patients. The aim is to identify the optimal dose and any short-term side effects.
• Phase III: Confirms the therapeutic benefits of the drug in a much larger patient population.
• Data collected in this phase forms the basis for marketing approval. It also explores various dose-response relationships and the drug’s safety in combination with other treatments.
• Phase IV: Post-marketing studies that occur after the drug has been approved for use. These studies gather further information on the drug’s long-term safety, efficacy, and optimal use conditions.

A practical note for 2026: the New Drugs and Clinical Trials (Amendment) Rules, effective March 7, 2026, reduced the standard regulatory review timeline from 90 to 45 working days for clinical trial applications. This is a significant operational improvement for sponsors planning trials in India and reflects CDSCO’s continued effort to streamline the approval process while maintaining ethical safeguards.

Controlled Human Infection Studies (CHIS)

According to the guidelines, Controlled Human Infection Studies (CHIS) are a unique category of research where healthy participants are intentionally exposed to an infectious agent under controlled conditions. These studies play a critical role in understanding disease pathophysiology, developing vaccines, and evaluating new chemical entities.

CHIS requires strict adherence to ethical standards to minimize risk to participants while maximizing the potential benefits of the research.

Confidentiality and Ethical Considerations

A fundamental component of GCP is the assurance of confidentiality. Researchers are required to maintain the privacy of study participants, ensuring that their identities and medical information are protected.

The guidelines also address the importance of confidentiality agreements, which bind all parties involved in the research to uphold the privacy of both participants and the sponsor’s proprietary information. In addition to confidentiality, the guidelines stress the importance of obtaining informed consent from participants, which includes full disclosure of the study’s risks and benefits.

For minors or individuals unable to provide consent, assent from the individual, along with the consent of a legal guardian, is required.

In 2026, confidentiality and data protection obligations for clinical trial sponsors in India have expanded beyond GCP frameworks alone. India’s Digital Personal Data Protection Rules, published in November 2025 under the Digital Personal Data Protection Act 2023, impose new requirements on how personal data, including health data collected during trials, is processed, stored, and protected. Sponsors should ensure their data management plans address both CDSCO GCP requirements and DPDP Act compliance, which operates on an 18-month phased implementation timeline.

Additionally, the 2024 CDSCO draft guidelines specifically require audio-visual recording of informed consent in certain circumstances, and introduce formal provisions for electronic informed consent processes. Both changes affect how sponsors document participant consent and maintain the related records.

Conclusion

The CDSCO’s GCP guidelines represent a significant step forward in standardizing and modernizing clinical research in India. The 2024 draft guidelines closed their public consultation period and — as of the time of this update — manufacturers and sponsors should confirm the current finalization status directly with CDSCO, as the timeline for adoption has not been publicly confirmed.

What is clear is the broader direction. India’s regulatory environment for clinical trials has been actively modernized through a series of developments in 2025 and 2026: the finalization of ICH E6(R3) globally, the introduction of the Digital Personal Data Protection Rules, the digital-only submission requirement for Cell and Gene Therapeutics, and the New Drugs and Clinical Trials Amendment Rules effective March 2026 — which introduced a prior intimation pathway for lower-risk activities and cut review timelines in half. Together, these changes signal India’s commitment to becoming a more competitive and efficient destination for global clinical research while maintaining strong ethical safeguards.

Sponsors conducting or planning trials in India should monitor CDSCO communications for GCP guideline finalization and ensure their trial frameworks are aligned with both Indian requirements and the now-effective ICH E6(R3) standard.

Source

https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTE4OTU=

How Can RegDesk Help?

RegDesk is an AI-powered Regulatory Information Management System (RIMS) designed to simplify global compliance for medical device companies. With regulatory intelligence covering 120+ markets, RegDesk helps you prepare and publish global submissions, manage standards, conduct impact assessments, and stay ahead of regulatory changes all from a single, centralized platform.

As India’s regulatory environment continues to evolve, with new NDCT Amendment Rules in effect, the DPDP Rules introducing data protection obligations for clinical trial sponsors, and CDSCO GCP guidelines moving toward finalization, staying ahead of these changes requires real-time intelligence, not periodic reviews. Expanding into new markets, including India, has never been more manageable with RegDesk.